Shop
-1.png)
eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
Biotics Research is proud to expand our commitment to education with the Wellness Unfiltered Pro Podcast. Each episode delves into key health topics and the clinical applications of our premier products. Through candid, insightful conversations, our team offers practical guidance to keep you informed and empowered as a healthcare professional.
November 29 2025
JAMA Dermatology has recently published the results of a retrospective cohort study evaluating the efficacy of supplementation with nicotinamide, vita...
JAMA Dermatology has recently published the results of a retrospective cohort study evaluating the efficacy of supplementation with nicotinamide, vitamin B3, for the prevention of skin cancer. This study included data from nearly 34,000 patients in the Veterans Affairs Corporate Data Warehouse over a 25-year period, with analyses conducted both for the general population and a subset of recipients of solid organ transplants. Patients were considered exposed to nicotinamide if they had taken it at a dose of 500mg twice per day for at least 30 days, with the main outcome being time to the next skin cancer after baseline.
Overall, they report a significant 14% reduction in skin cancer risk with nicotinamide use, though if nicotinamide was initiated after the first skin cancer, the risk reduction was as high as 54%. The benefit declined when initiated after subsequent skin cancers, suggesting that supplementation after the initial skin cancer may have the largest preventative effect. A risk reduction was observed for skin cancers overall, basal cell carcinoma, and especially cutaneous squamous cell carcinoma.
While this was not a randomized trial, its large patient population does buttress a previously published phase 3 randomized and controlled trial, which found a 23% reduction in the risk for new non-melanoma skin cancers when supplemented at 500mg twice per day by people with a history of at least two non-melanoma skin cancers within the last 5 years. This study also reported a 13% lower incidence of actinic keratoses by the end of the 12-month study, with no difference in adverse events between groups over the course of the study.
Submit this form and you'll receive our latest news and updates.
Recent research has found that cannabinoids’ ability to help modulate the body’s natural inflammatory response may be be...
Learn more
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
Proposition 65 Warning
© 2025 Biotics Research Corporation - All Rights Reserved
Submit your comment